Triple negative breast cancer vaccines
Active Awarded Last action
- Contract number
- 75N91026F00001
- Awardee
-
University Of Oklahoma UEI GY8NMUZQXVS7
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,147,754
Award facts
- Opportunity
-
- TORFP2026E03 Solicitation number
- Contract value 100% obligated
- $1,147,754.00 Current and potential, with all options
- Completion date 5% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Oklahoma City, OK 73104, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
The National Cancer Institute issued a delivery order to the University of Oklahoma Health Sciences Center on September 14, 2026, with a ceiling value of $1,147,754, under the PRECLINICAL EFFICACY & INTERMEDIATE ENDPOINT BIOMARKERS IDIQ for triple negative breast cancer vaccine development under the PREVENT Cancer Preclinical Drug Development Program.
Place of performance is Oklahoma City, OK. The order carries a firm fixed price and an ultimate completion date of September 13, 2028. The scope encompasses preclinical efficacy and intermediate endpoint evaluation to support vaccine candidate advancement toward clinical translation.
Quick answers
Who was awarded contract 75N91026F00001?
75N91026F00001 was awarded to University Of Oklahoma by National Cancer Institute (National Institutes of Health) on September 14, 2026.
How much is contract 75N91026F00001 worth?
The government has obligated $1,147,754 on 75N91026F00001.
Is contract 75N91026F00001 an order under another contract?
Yes. 75N91026F00001 is a delivery order under 75N91024D00005, an indefinite delivery contract, on PRECLINICAL EFFICACY & INTERMEDIATE ENDPOINT BIOMARKERS IDIQ.
Was contract 75N91026F00001 competed?
The extent of competition for 75N91026F00001 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award